ACEi/ ARB and Deaths of COVID-19 Patients-Reference-Cited by-同舟云学术

ACEi/ ARB and Deaths of COVID-19 Patients

Published:2022-08 Issue:2 Volume:18 Page:158-162
ISSN:1573-4021
Container-title:Current Hypertension Reviews
language:en
Short-container-title:CHYR

Author:

Kumar Anoop¹^ORCID,Azad Gulam Navi²

Affiliation:

1. Department of Pharmacology, Delhi Pharmaceutical Sciences & Research University (DPSRU)-New Delhi, India

2. Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research (NIPER), Raebareli, Lucknow (U.P.), India

Abstract

Abstract: The practice of angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers (ACEi/ARB) in COVID-19 hypertensive patients is still an open question for clinicians to answer. The present study was conducted to find out the association between the use of ACEI/ARB and the mortality rate of COVID-19 patients. The search was conducted from December 2019 to October 2020 in PubMed to identify relevant published studies. RevMan 5 was used for the analysis of the data. The random-effect model was used to calculate the odds ratio. In total, 07 studies were found to be appropriate, reporting a total of 1,566 subjects. The odds ratio was found to be 0.86 [0.41, 1.81], indicating no association between ACEI/ARB and the mortality rate of COVID-19 patients. In conclusion, we may suggest continuing the use of ACEi/ARB in COVID-19 patients till further pieces of evidence are generated.

Publisher

Bentham Science Publishers Ltd.

Subject

Internal Medicine

Reference17 articles.

1. Wu Z.; McGoogan J.M.; Characteristics of and important lessons from the coronavirusdisease 2019 (COVID-19) outbreak in China: Summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA 2020,323(13),1239-1242

2. Sanyaolu A.; Okorie C.; Marinkovic A.; Comorbidity and its impact on patients with COVID-19. SN Compr Clin Med 2020,2(8),1-8

3. Hoffmann M.; Kleine-Weber H.; Schroeder S.; SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020,181(2),271-280.e8

4. Albini A.; Noonan D.M.; Pelosi G.; Di Guardo G.; Lombardo M.; The SARS-CoV-2 receptor, ACE-2, is expressed on many different cell types: Implications for ACE-inhibitor- and angiotensin II receptor blocker-based antihypertensive therapies-reply. Intern Emerg Med 2020,15(8),1583-1584

5. Zhang P.; Zhu L.; Cai J.; Association of inpatient use of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19. Circ Res 2020,126(12),1671-1681

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of the chronic medication use on outcome measures of hospitalized COVID-19 patients: Evidence from big data;Frontiers in Public Health;2023-02-24

2. Evaluation of the Association between Multilobar Involvement and ACE Inhibitor Use in SARS-CoV-2 Patients;Medical Bulletin of Haseki;2023-02-15

3. Incidence and potential risk factors for remdesivir-associated bradycardia in hospitalized patients with COVID-19: A retrospective cohort study;Frontiers in Pharmacology;2023-02-01

4. Coronavirus disease 2019 and cardiovascular disease;Tzu Chi Medical Journal;2023

5. Associations between Periodontitis, COVID-19, and Cardiometabolic Complications: Molecular Mechanisms and Clinical Evidence;Metabolites;2022-12-26